Company Profile
Shine-On Biomedical Co., Ltd. was established on April 6th, 2021 by Dr. Chiu-Chin Huang.
The company has developed a series of first-in-human novel drugs that are based on the innovative technology platforms of “targeted exosome for drug delivery” and “trispecific T-cell engager antibody”. The Company has various technical patents for the exosomes and multi-specific antibody drugs. ShineOn collaborated with worldwide renown research institutes, international capable CDMO/CRO companies and professional expert consulting groups to create new biological drugs to treat patients with cancers. According to the Cortellis database, ShineOn is ranked among the top ten companies worldwide for developing "next-generation" targeted exosome therapeutic drugs and multi-specific antibody drugs.
The company was successfully listed on the Emerging Stock Market of Taipei Exchange (code 6926) in November 2022.
The company has developed a series of first-in-human novel drugs that are based on the innovative technology platforms of “targeted exosome for drug delivery” and “trispecific T-cell engager antibody”. The Company has various technical patents for the exosomes and multi-specific antibody drugs. ShineOn collaborated with worldwide renown research institutes, international capable CDMO/CRO companies and professional expert consulting groups to create new biological drugs to treat patients with cancers. According to the Cortellis database, ShineOn is ranked among the top ten companies worldwide for developing "next-generation" targeted exosome therapeutic drugs and multi-specific antibody drugs.
The company was successfully listed on the Emerging Stock Market of Taipei Exchange (code 6926) in November 2022.